Dermatomyositis

Overview

• Definition: Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by immune-mediated injury affecting primarily the skin and proximal musculature. It is distinguished from other inflammatory myopathies by specific cutaneous features and a prominent association with malignancy.
• Epidemiology:
  • Incidence: Approximately 9.6 cases per million persons/year.
  • Prevalence: Estimated at 2 to 10 cases per 100,000 persons.
  • Demographics: Bimodal distribution peaking in childhood (juvenile DM, 5-15 years) and adulthood (40-60 years).
  • Sex: More common in females than males (ratio approximately 2:1).
  • Race: Higher incidence reported in African American populations.
• Classification:
  • Classic Dermatomyositis: Typical skin rash preceding or concurrent with proximal muscle weakness.
  • Amyopathic Dermatomyositis (ADM) or Clinically Amyopathic Myositis (CAM) (DM sine myositis): Characteristic cutaneous findings without clinical muscle weakness for at least six months. Muscle enzyme levels may be normal or only mildly elevated.
  • Hypomyopathic Dermatomyositis: Characteristic skin findings with subtle or subclinical muscle weakness or myositis on imaging/biopsy, but without overt signs of muscle disease.
  • Juvenile Dermatomyositis (JDM): Onset before age 18, often associated with calcinosis and vasculopathy.
  • Dermatomyositis associated with malignancy (Cancer-Associated DM): DM diagnosed concurrently, preceding, or following cancer diagnosis (usually within 3 years).

Pathophysiology

• Mechanism: DM is characterized by a complement-mediated microangiopathy affecting endomysial capillaries and arterioles. The primary mechanism is thought to be humoral:
  • Skin/Muscle: Thought to be mediated by type I interferon signatures, activated plasmacytoid dendritic cells, C5b-9 deposition around endomysial capillaries, and perivascular/perifascicular inflammation (primarily B cells and CD4+ T cells).
  • Autoantibodies: Highly heterogeneous, associated with clinical subtypes (e.g., anti-synthetase syndrome, anti-melanoma differentiation-associated gene 5 [MDA5], anti-Mi-2).
• Risk Factors:
  • Genetic: Association with specific HLA haplotypes (e.g., HLA-DRB1*0301).
  • Environmental: Exposure to ultraviolet (UV) light (triggering interferon pathways), infections (Parvovirus B19, Coxsackievirus B), and certain medications (e.g., hydroxyurea).
  • Malignancy: Age over 40-50 years is a significant risk factor for malignancy-associated DM.
  • Autoimmunity: Coexistence with other connective tissue diseases.
• Protective Factors: None definitively proven; strict UV avoidance may prevent skin flares.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  1. Proximal Muscle Weakness: Symmetrical, insidious onset, affecting the shoulder and hip girdles (difficulty rising from chairs, climbing stairs, combing hair). Usually painless.
  2. Cutaneous Manifestations: Highly specific and often pathognomonic.
• Early Signs: Fatigue, low-grade fever, dysphagia (25-40%), Raynaud phenomenon.
• Advanced Signs: Severe muscle atrophy, contractures, interstitial lung disease (ILD), respiratory failure (due to pharyngeal/diaphragmatic weakness), and calcinosis (especially in JDM).
• Atypical Presentations: Amyopathic DM (no muscle weakness), hypomyopathic DM, overlap syndrome features (e.g., skin rash with scleroderma features).

Physical Examination

• Inspection:
  • Heliotrope Rash: Periorbital erythema and edema, imparting a purplish discoloration (violaceous hue). Highly specific.
  • Gottron Papules: Erythematous to violaceous papules over the extensor surfaces of the metacarpophalangeal (MCP) and interphalangeal (IP) joints. Pathognomonic.
  • Gottron Sign: Erythema over the elbows and knees.
  • V-Sign/Shawl Sign: Macular erythema over the anterior neck/chest (V-sign) or posterior shoulder/upper back (shawl sign), often exacerbated by sun exposure.
  • Holster Sign: Erythema and poikiloderma on the lateral thighs.
  • Periungual Telangiectasias: Capillary loop abnormalities visualized at the nailfolds.
  • Calcinosis Cutis: Subcutaneous calcium deposits (nodules), most common in JDM.
• Palpation: Symmetric proximal muscle weakness (grades 3 or 4/5), often non-tender, though occasionally muscle tenderness (myalgia) may be present. Palpable subcutaneous calcinosis.
• Special Tests:
  • Manual Muscle Testing (MMT): Using the Medical Research Council (MRC) scale or quantitative myometry to assess strength objectively.
  • Time Trials: Assessing the time it takes to perform tasks (e.g., rising from a chair, 6-minute walk test).

Diagnostic Approach

History Taking

• Key Questions:
  • Onset, location, and progression of muscle weakness (ask specifically about difficulty running, climbing stairs, rising from low seats).
  • Presence and characteristics of skin lesions (onset relative to muscle weakness, photosensitivity).
  • Constitutional symptoms (fever, weight loss, fatigue).
  • Symptoms of dysphagia (choking, regurgitation, voice changes).
  • Respiratory symptoms (cough, shortness of breath—indicating ILD).
  • Detailed cancer screening history and age.
• Red Flags:
  • Rapidly progressive muscle weakness (indicates need for aggressive immunosuppression).
  • Significant dysphagia or dyspnea (risk of aspiration and respiratory failure).
  • Rapidly progressive ILD (often associated with anti-MDA5 or anti-synthetase antibodies).
  • Evidence of malignancy (e.g., unexplained weight loss, specific screening abnormalities).

Laboratory Tests

DM diagnosis relies on a combination of clinical features, elevated muscle enzymes, characteristic autoantibodies, and, if necessary, muscle biopsy.

• First-Line:
  • Muscle Enzymes: Creatine kinase (CK), aldolase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH). CK is often highly elevated (range 10x to 50x upper limit of normal [ULN]).
  • Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are often normal or only mildly elevated, contrasting with other inflammatory conditions.
  • Autoantibodies (Myositis Panel): Screen for Myositis-Specific Antibodies (MSAs) and Myositis-Associated Antibodies (MAAs).
    • MSAs include: Anti-Mi-2 (classic DM, good prognosis), Anti-MDA5 (amyopathic DM, severe ILD), Anti-TIF1-$\gamma$ (strongest predictor of cancer-associated DM), Anti-NXP-2 (calcinosis, malignancy), Anti-Synthetase Abs (Jo-1, PL-7, PL-12, etc.—associated with Anti-Synthetase Syndrome: myositis, ILD, Raynaud, arthralgia, mechanic’s hands).
• Confirmatory:
  • Muscle Biopsy: If diagnosis is uncertain or overlap syndrome is suspected.
    • Findings in DM: Perifascicular atrophy, perivascular and perimysial inflammation (lymphocytic infiltrate). Specific features of microangiopathy (C5b-9 deposition).
• Monitoring: CK and aldolase levels are used to monitor disease activity and response to therapy, though clinical strength remains the gold standard.

Imaging

• Recommended:
  • Magnetic Resonance Imaging (MRI): Thighs (or affected limbs) is highly sensitive for identifying active muscle inflammation (edema, T2 signal intensity increase) and guiding muscle biopsy location (avoiding areas of chronic damage or fat replacement).
  • Chest CT (High-Resolution HRCT): Mandated for all patients to screen for subclinical interstitial lung disease (ILD), especially if anti-synthetase or anti-MDA5 antibodies are present.
• Advanced:
  • Positron Emission Tomography (PET) - CT: Used in the workup for malignancy-associated DM when initial cancer screening is negative but suspicion remains high (e.g., Anti-TIF1-$\gamma$ positive or age >50).
  • Electromyography (EMG): Used primarily to distinguish myopathic from neuropathic causes of weakness. Findings include fibrillation potentials, positive sharp waves, and polyphasic motor units of low amplitude and short duration. (Less specific than MRI or biopsy).

Management

Management goals are to restore muscle strength and function, control dermatologic disease, and treat systemic manifestations (especially ILD and malignancy).

Acute Management

• Immediate: If severe dysphagia or rapidly deteriorating respiratory function due to diaphragmatic weakness: Airway support, initiation of high-dose glucocorticoids, and potential transition to intravenous immunoglobulin (IVIg).
• Stabilization: Initiation of high-dose corticosteroids (see Chronic Management).
• Emergency: Management of severe, rapidly progressive ILD (e.g., in anti-MDA5 cases) often requires combination therapy: High-dose steroids AND calcineurin inhibitors (e.g., tacrolimus) or cyclophosphamide.

Chronic Management

• Pharmacological:
  • Glucocorticoids (First-Line Induction): Prednisone 1 mg/kg/day (usually 40–80 mg daily, maximum 100 mg) or equivalent IV methylprednisolone (1 g daily for 3 days for severe disease). Taper should begin only after muscle strength plateaus and enzymes normalize (often over 6–12 weeks), aiming for the lowest effective maintenance dose (usually <7.5 mg/day).
  • Immunosuppressive Sparing Agents (First-Line): Used to maintain remission and minimize steroid toxicity.
    • Methotrexate (MTX): 15–25 mg/week PO/SC. Effective for skin and muscle disease.
    • Azathioprine (AZA): 1.5–3.0 mg/kg/day PO. Slower onset than MTX.
    • Mycophenolate Mofetil (MMF): 1.0–3.0 g/day PO. Preferred agent for associated ILD.
  • Rituximab (Anti-CD20): Used for refractory cases, especially those with ILD or severe muscle weakness. Standard dose: 1000 mg IV on days 1 and 15, repeated every 6 months.
  • Calcineurin Inhibitors (e.g., Tacrolimus, Cyclosporine): Used particularly for DM with ILD, often in combination with MMF or high-dose steroids.
  • Antimalarials: Hydroxychloroquine (HCQ) 200–400 mg/day. Essential for skin disease management, but less effective for muscle weakness. Caution: Monitor eyes; screen for G6PD deficiency if considering chloroquine.
• Non-pharmacological:
  • Physical Therapy: Crucial for preventing atrophy, contractures, and restoring muscle function once acute inflammation is controlled. Should be initiated when CK levels begin trending down.
  • Sun Protection: Strict UV avoidance (broad-spectrum sunscreen SPF 30+, protective clothing) is mandatory to prevent characteristic skin flares and potential disease exacerbation.
  • Dietary/Supportive Care: Calcium and Vitamin D supplementation (for steroid-induced osteoporosis risk). Swallowing therapy for dysphagia.

Treatment Algorithms

• First-Line: High-dose oral glucocorticoids PLUS a steroid-sparing agent (MTX or AZA). Add HCQ for skin disease.
• Second-Line: If poor response after 3–6 months (failure of strength or enzyme normalization): Switch steroid-sparing agent (e.g., MMF) OR add/switch to IVIg (2 g/kg, divided over 2-5 days once monthly) OR transition to Rituximab.
• Refractory Cases: Consider IVIg, high-dose biologic agents (Rituximab), cyclophosphamide (especially for severe ILD), or referral to specialized center.

Complications

• Common: Muscle atrophy, weakness leading to functional impairment, complications of chronic steroid use (osteoporosis, cataracts, diabetes, infection).
• Serious:
  • Interstitial Lung Disease (ILD): Leading cause of death, especially acute/subacute ILD associated with anti-MDA5 antibodies.
  • Malignancy: Increased risk (up to 4-9 times higher than general population), mainly lung, ovarian, gastrointestinal, and nasopharyngeal cancer. Most commonly diagnosed within 1 year of DM onset.
  • Aspiration Pneumonia: Due to pharyngeal/esophageal muscle weakness (dysphagia).
  • Cardiac Involvement: Myocarditis, heart failure, conduction defects.
• Long-term: Calcinosis cutis (especially JDM), joint contractures, physical disability.

Prognosis

• Factors:
  • Favorable: Anti-Mi-2 positivity, isolated myositis without systemic involvement, JDM (mostly non-malignancy related).
  • Poor: Elderly age, high disease activity at presentation, presence of dysphagia, presence of ILD (especially acute/rapidly progressive form associated with Anti-MDA5 or Anti-Synthetase antibodies), and associated malignancy (poorer survival driven by the cancer).
• Survival: 5-year survival rates range from 70% to 90%. Mortality is significantly higher in cancer-associated DM and DM with severe ILD.
• Quality of Life: Significantly impacted by residual weakness, fatigue, chronic pain, and steroid-related adverse effects.

Prevention

• Primary: Not possible due to the autoimmune nature.
• Secondary: Aggressive screening for associated malignancy, especially in the first 3 years post-diagnosis and in high-risk categories (Anti-TIF1-$\gamma$, age >40). Screening protocols often include age- and sex-appropriate conventional screening PLUS PET-CT and colonoscopy if initial screening is negative.
• Tertiary: Preventing complications through strict sun protection, rigorous physical therapy, and careful monitoring for ILD and steroid side effects. Prophylaxis for Pneumocystis jirovecii pneumonia (PJP) should be considered for patients on high-dose steroids and MMF/AZA/Rituximab.

Special Populations

• Pediatric (JDM): Increased frequency of vasculitis, lipodystrophy, and extensive calcinosis. Treatment tends to be similar, but risk of malignancy is substantially lower. Long-term surveillance for calcinosis is key.
• Geriatric: Increased severity and frequency of dysphagia, higher risk of ILD, and very high imperative for malignancy screening. Steroid-sparing agents are often prioritized early due to high risk of steroid toxicity.
• Pregnancy: DM is rare during pregnancy. Active disease poses risks (preterm birth, fetal demise). Treatment strategy involves agents deemed safer: High-dose steroids (prednisone), AZA, or IVIg. MTX and cyclophosphamide are strictly contraindicated (teratogenic).
• Comorbidities:
  • ILD: Require aggressive combination therapy, often Tacrolimus/Cyclosporine + MMF + steroids.
  • Malignancy: Focus shifts to treating the underlying cancer, which often leads to improvement in DM symptoms (paraneoplastic phenomenon).

Clinical Pearls

• Diagnostic: Always check for the three key features: Heliotrope rash, Gottron's papules/sign, and symmetrical proximal weakness. If only skin disease is present, consider Amyopathic DM and rigorously screen for ILD (especially if anti-MDA5 positive).
• Treatment: Corticosteroids treat muscle inflammation quickly, but a steroid-sparing agent must be initiated immediately to allow for eventual steroid taper and long-term control. Recovery of muscle strength always lags derrière normalization of CK levels.
• Pitfalls:
  1. Misdiagnosing cutaneous DM (ADM) as lupus or simply contact dermatitis, missing progressive ILD.
  2. Failure to screen aggressively for malignancy in high-risk groups.
  3. Prematurely stopping physical activity; movement is critical once inflammation is controlled.

Recent Updates

• Guidelines: EULAR/ACR 2017 revised diagnostic criteria emphasize autoantibody profiling and imaging (MRI) over reliance on EMG and biopsy alone for initial diagnosis.
• Evidence: Growing evidence supports the use of Rituximab as a standard second-line agent, and MMF or Calcineurin inhibitors (tacrolimus) as preferred first-line adjuncts when ILD is present, particularly in anti-synthetase syndrome.
• Controversies: Optimal screening duration for malignancy (some experts advocate for extended screening (>3 years) given anti-TIF1-$\gamma$ association), and the precise role of Janus Kinase (JAK) inhibitors in refractory skin disease and ILD.

Key References

• Guidelines: European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) guidelines for classification and management of inflammatory myopathies (2017).
• Studies: Studies defining the significance of specific myositis autoantibodies (e.g., TIF1-$\gamma$ and malignancy risk; MDA5 and rapidly progressive ILD).
• Reviews: UpToDate, Gene, and relevant reviews in Lancet and Arthritis & Rheumatology covering DM pathogenesis and treatment.

---

Disclaimer: This information is intended for clinical reference by medical professionals. It is not a substitute for professional medical judgment, diagnosis, or patient-specific treatment decisions. Dosing and therapeutic approaches must be individualized based on patient characteristics and local institutional guidelines.